"Q3 was another step forward in our Win-in-MRD strategy. We delivered 4,388 clinical tests, a 26% sequential and 364% year-over-year growth and now have 700-plus physicians ordering NeXT Personal." (CEO)
"While biopharma project timing continues to have variability, the underlying MRD demand is strong, clinical adoption is compounding and our cash position gives us the flexibility to execute." (CEO)
"Our assay demonstrated a median lead time of 5 months in detecting MRD progression ahead of imaging and standard expert review. Lead time is a difference maker for patients, underscoring the value of an ultrasensitive approach for earlier intervention." (CEO，引用 LAURA 试验数据)
"We are being prudent by balancing test volume and margin dilution... Longer term, we expect total company margins to expand beyond 50% once we have obtained reimbursement coverage for more than a few indications, and we also achieved greater revenue scale." (CFO)
Prepared Metrics
指标
数值
来源/背景
总营收
$14.5M
Q3 2025 (CFO)
生物制药营收
$13.2M
Q3 2025 (CFO)
临床营收
$0.4M
Q3 2025 (CFO)
毛利率
13.2%
Q3 2025 (CFO)
毛利率（剔除临床投资）
~31%
Q3 2025 调整后 (CFO)
净亏损
$21.7M
Q3 2025 (CFO)
现金与短期投资
$150.5M
截至 Q3 末 (CFO)
2025全年营收指引
$68M – $73M
下调后区间 (CFO)
2025全年净亏损指引
~$85M
维持不变 (CFO)
2025全年现金消耗指引
~$75M
维持不变 (CFO)
Q&A Batch (1-5 of 7)
Q1 — Thomas Flaten
Topic: Large customer onboarding update and customs delay impact on Q4 guidance
Key points:
Two large customers both came online; one drove ~1/3 of Q3 revenue from MRD, the other contributed some revenue in Q3 and will bleed into Q4.
MRD revenue growing 3x this year; signed 2 large prospective clinical trials with biopharma customers to be serviced over next 2–3 years.
Logistical delay: samples faced customs problems (possibly due to government shutdown); one sample cohort turned around, may slip into Q1 if not received in Q4.
Mgmt stance: Neutral — widened Q4 guidance range on the bottom end due to customs uncertainty, but remains optimistic samples will flow.
Q2 — Mark Massaro
Topic: NeXT Personal growth rate, Q4 clinical revenue guidance, MolDX progress, and MRD biopharma feedback
Key points:
NeXT Personal growth was +26% in Q3, below prior 30%–40% quarterly target; mgmt says they were “thoughtful” managing investment ahead of reimbursement, and Q3 is seasonally flat (Q2/Q4 are bigger).
Lowered Q4 clinical revenue guidance; 3 MolDX dossiers (breast, IO, lung) are in active review, with 2 expected by year-end; process involves 60-day cycles of questions/answers.
Biopharma feedback on 1 part-per-million sensitivity: enables faster trial failure (40% of positive results inside that range), earlier success in later-stage trials, and better patient enrollment confidence.
Mgmt stance: Bullish — MolDX conversations “positive and productive”; MRD demand high, with biopharma being “most discriminating buyers” but showing strong engagement.
Q3 — Daniel Brennan
Topic: Government shutdown impact on MolDX, MolDX review cadence, and confidence in year-end approvals
Key points:
No impact from government shutdown seen yet on MolDX; MolDX is a private company with a contract, so not affected.
MolDX review follows ~2-month cycles: submission → 60 days for questions → response → clock restarts; breast filed in April, IO and lung also in process.
Mgmt expects 2 approvals by year-end, but notes variability; TRACERx data (lung) is “phenomenal,” IO study has 200+ patients across 18 cancers, breast data strong.
Mgmt stance: Bullish — evidence strength derisks process; even if approvals slip into next year, “none of this is make or break” for trajectory.
Q4 — Thomas VonDerVellen
Topic: Biopharma customer account size, pipeline growth, and financial discipline
Key points:
Large pharma customers (e.g., ~$5M each) have potential for more than $5M per account as penetration deepens; early stages of capturing 100% share.
MRD pipeline and funnel have grown rapidly over last 2 quarters; near-term headwinds from sample receipt delays on translational research side.
Natera and Moderna declines expected (Moderna Phase III melanoma trial ended; Natera winding down); still growing biopharma revenue 40% this year.
Cash usage guidance unchanged; mgmt focused on financial discipline and prudent spending.